Aeterna Zentaris Inc., of Charleston, S.C., said it entered a securities purchase agreement with institutional investors to purchase about $5 million of common shares in a registered direct offering and warrants to purchase common shares in a concurrent private placement. The combined purchase price for one common share and one warrant will be $1.50. Under the terms, Aeterna agreed to sell 3.3 million shares and to issue warrants to purchase up to an aggregate of 3.3 million common shares. Maxim Group LLC is acting as sole placement agent.
Briacell Therapeutics Corp., of Berkeley, Calif., disclosed a nonbrokered private placement of up to about 8.6 million shares for gross proceeds of up to about C$600,000 (US$453,461) at a price per common share of C7 cents. The company, which is developing immunotherapy for advanced breast cancer, intends to use proceeds to fund research and development and for general working capital and corporate purposes.
Curamir Therapeutics Inc., of Woburn, Mass., was launched by Delos Capital, with a $10 million series A financing to support work on micro RNA-based cancer therapeutics. Curamir is incubated through a licensing collaboration with the State University of New York and co-founded by veterans in the field of gene regulation and translational medicine: Jingfang Ju, professor of the Department of Pathology at Stony Brook University; James D. Watson, co-discoverer of the DNA structure and a 1962 Nobel Laureate; and Lan Bo Chen, professor emeritus of pathology at Harvard Medical School and an academician of the Academia Sinica of Taiwan.